tradingkey.logo

Biomerica Inc

BMRA
2.250USD
-0.020-0.88%
Close 02/06, 16:00ETQuotes delayed by 15 min
6.63MMarket Cap
LossP/E TTM

Biomerica Inc

2.250
-0.020-0.88%

More Details of Biomerica Inc Company

Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.

Biomerica Inc Info

Ticker SymbolBMRA
Company nameBiomerica Inc
IPO dateMar 17, 1980
CEOIrani (Zackary S)
Number of employees53
Security typeOrdinary Share
Fiscal year-endMar 17
Address17571 Von Karman Avenue
CityIRVINE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92614
Phone19493792875
Websitehttps://biomerica.com/
Ticker SymbolBMRA
IPO dateMar 17, 1980
CEOIrani (Zackary S)

Company Executives of Biomerica Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Zackary S. Irani
Mr. Zackary S. Irani
Chief Executive Officer, Director
Chief Executive Officer, Director
219.13K
+52500.00%
Mr. Gary Lu
Mr. Gary Lu
Chief Financial Officer
Chief Financial Officer
64.53K
+40000.00%
Mr. David Moatazedi
Mr. David Moatazedi
Independent Director
Independent Director
41.25K
+20000.00%
Mr. Eric Chin
Mr. Eric Chin
Independent Director
Independent Director
32.50K
+22500.00%
Mr. Allen C. Barbieri
Mr. Allen C. Barbieri
Executive Vice Chairperson of the Board and Corporate Secretary
Executive Vice Chairperson of the Board and Corporate Secretary
--
--
Dr. Jane F. Emerson, M.D., Ph.D.
Dr. Jane F. Emerson, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott Madel
Mr. Scott Madel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Gary M. Huff
Mr. Gary M. Huff
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Zackary S. Irani
Mr. Zackary S. Irani
Chief Executive Officer, Director
Chief Executive Officer, Director
219.13K
+52500.00%
Mr. Gary Lu
Mr. Gary Lu
Chief Financial Officer
Chief Financial Officer
64.53K
+40000.00%
Mr. David Moatazedi
Mr. David Moatazedi
Independent Director
Independent Director
41.25K
+20000.00%
Mr. Eric Chin
Mr. Eric Chin
Independent Director
Independent Director
32.50K
+22500.00%
Mr. Allen C. Barbieri
Mr. Allen C. Barbieri
Executive Vice Chairperson of the Board and Corporate Secretary
Executive Vice Chairperson of the Board and Corporate Secretary
--
--
Dr. Jane F. Emerson, M.D., Ph.D.
Dr. Jane F. Emerson, M.D., Ph.D.
Independent Director
Independent Director
--
--

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Clinical Lab
1.02M
74.20%
Contract Manufacturing
192.00K
13.91%
OTC
161.00K
11.67%
Physicians’ Office
3.00K
0.22%
By RegionUSD
Name
Revenue
Proportion
Asia
670.00K
48.55%
United States
318.00K
23.04%
Europe
305.00K
22.10%
Middle East
85.00K
6.16%
South America
2.00K
0.14%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Clinical Lab
1.02M
74.20%
Contract Manufacturing
192.00K
13.91%
OTC
161.00K
11.67%
Physicians’ Office
3.00K
0.22%

Shareholding Stats

Updated: Sun, Jan 25
Updated: Sun, Jan 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Irani (Zackary S)
7.26%
Barbieri (Allen)
2.23%
Lu (Gary)
2.14%
Moatazedi (David)
1.37%
Chin (Eric)
1.08%
Other
85.94%
Shareholders
Shareholders
Proportion
Irani (Zackary S)
7.26%
Barbieri (Allen)
2.23%
Lu (Gary)
2.14%
Moatazedi (David)
1.37%
Chin (Eric)
1.08%
Other
85.94%
Shareholder Types
Shareholders
Proportion
Individual Investor
15.59%
Investment Advisor
1.98%
Investment Advisor/Hedge Fund
0.76%
Hedge Fund
0.35%
Research Firm
0.03%
Other
81.28%

Institutional Shareholding

Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
61
88.80K
11.10%
--
2025Q3
66
109.78K
12.53%
+19.30K
2025Q2
64
90.48K
15.22%
-57.30K
2025Q1
68
147.78K
21.33%
-341.18K
2024Q4
67
244.57K
22.09%
-15.39K
2024Q3
66
259.96K
25.76%
-100.07K
2024Q2
66
360.04K
29.98%
-224.63K
2024Q1
64
584.66K
28.76%
-20.09K
2023Q4
60
562.02K
30.44%
-39.83K
2023Q3
60
602.09K
33.14%
-52.42K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Irani (Zackary S)
219.13K
7.43%
+52.50K
+31.51%
Dec 12, 2025
Barbieri (Allen)
67.29K
2.28%
+30.00K
+80.44%
Dec 12, 2025
Lu (Gary)
64.53K
2.19%
+40.00K
+163.05%
Dec 12, 2025
Moatazedi (David)
41.25K
1.4%
+20.00K
+94.12%
Dec 12, 2025
Chin (Eric)
10.00K
0.34%
--
--
Oct 17, 2025
Emerson (Jane)
30.13K
1.02%
+30.13K
--
Oct 17, 2025
The Vanguard Group, Inc.
21.13K
0.72%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
20.98K
0.71%
-680.00
-3.14%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
18.64K
0.63%
--
--
Sep 30, 2025
Coste (Catherine)
16.10K
0.55%
+10.63K
+194.10%
Dec 13, 2024
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
Apr 16, 2025
Merger
8→1
Date
Ex-dividend Date
Type
Ratio
Apr 16, 2025
Merger
8→1
KeyAI